Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.05 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.32 +12.1% TUNG 1.73 +2.4% LGO 1.00 −3.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.50 +1.1% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.05 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.32 +12.1% TUNG 1.73 +2.4% LGO 1.00 −3.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.50 +1.1% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0%
Management

COSCIENS Biopharma Inc. Announces Leadership Change

By The Northwire Desk — AI Analysis Nov 14, 2025 · 17:15 CSCI · 3.3 COSCIENS BIOPHARMA INC
CSCI · Price

Executive Summary

  • Peter H. Puccetti, CFA, Chairman of the Board, has been appointed Interim CEO of COSCIENS Biopharma Inc., effective immediately.
  • The appointment follows the resignation of former CEO Anna Biehn as the board seeks to reduce costs and streamline the organization.
  • Puccetti will continue to lead both the Board and the company while a permanent CEO is identified, signaling continuity in strategic direction.

Key Details

  • Interim CEO Appointment: Peter H. Puccetti assumes the role of Interim Chief Executive Officer effective immediately; he also retains his position as Chairman of the Board.
  • CEO Departure: Anna Biehn steps down from the CEO role; no further details on her departure were provided.
  • Board Statement: Robert Seager, Chair of the Human Resources, Nominating and Governance Committee, cited cost reduction, organizational streamlining, and alignment with strategic priorities as reasons for the leadership transition.
  • Interim CEO Outlook: Puccetti indicated his focus will be on strengthening operational performance and creating conditions to drive shareholder value.
  • Company Background (retained for context only): COSCIENS develops natural plant‑based active ingredients and commercializes pharmaceutical/diagnostic products, including the FDA‑approved oral test Macimorelin for adult growth hormone deficiency diagnosis.

Notable Quotes

“As the Company continues its efforts to reduce costs and streamline its organizational structure while aligning resources with key strategic priorities, the Board has determined that now is the right time to transition leadership.” – Robert Seager, Chair of the Human Resources, Nominating and Governance Committee

“In my expanded role as Chairman and Interim CEO, I plan on continuing to strengthen operational performance, while working to create the conditions necessary for driving shareholder value.” – Peter H. Puccetti, Interim CEO & Chairman

Materiality Assessment: Material – Neutral (CEO transition is a material corporate event that may affect investor perception but does not convey immediate financial impact).

Read the original news release →

More from COSCIENS BIOPHARMA INC

Jun 18, 2026 · 08:30

SEC deregistration cleared, permanent CEO installed, but cash runway remains tight.

Management May 12, 2026 · 17:05

COSCIENS Posts Accounting Profit Amidst Cash Burn and Program Cuts

Earnings Apr 20, 2026 · 08:00

COSCIENS Biopharma Proposes Share Consolidation to Cut Reporting Costs and Exit U.S. Registry

Other Mar 25, 2026 · 17:05

COSCIENS Sheds German Subsidiaries and $11M Pension Liability as Cash Burn Outpaces Declining Revenue

Earnings Mar 05, 2026 · 17:10

COSCIENS Provides Strategic Update

Other Dec 01, 2025 · 17:05

COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen(TM) in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

M&A / Property